GROUP II: Patients receive durvalumab IV over 60 minutes on days -1 and 28, (may occur as early as day 21), and JCAR014 IV over 20-30 minutes on day 0. Patients may receive durvalumab IV over 60 minutes every 4 weeks for up to 11 doses in the absence of disease progression or unacceptable toxicity.